home / stock / tara / tara quote
Last: | $2.03 |
---|---|
Change Percent: | 0.0% |
Open: | $2.09 |
Close: | $2.03 |
High: | $2.1 |
Low: | $2 |
Volume: | 65,496 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.03 | $2.09 | $2.03 | $2.1 | $2 | 65,496 | 07-02-2024 |
$2.09 | $2.07 | $2.09 | $2.24 | $2.06 | 68,809 | 07-01-2024 |
$2.08 | $2.22 | $2.08 | $2.31 | $2.04 | 219,103 | 06-28-2024 |
$2.17 | $1.93 | $2.17 | $2.35 | $1.9101 | 304,705 | 06-27-2024 |
$1.955 | $2.07 | $1.955 | $2.09 | $1.88 | 268,442 | 06-26-2024 |
$2.1 | $2.26 | $2.1 | $2.32 | $2.08 | 179,282 | 06-25-2024 |
$2.23 | $2.24 | $2.23 | $2.31 | $2.2 | 168,906 | 06-24-2024 |
$2.26 | $2.44 | $2.26 | $2.58 | $2.26 | 383,327 | 06-21-2024 |
$2.41 | $2.28 | $2.41 | $2.55 | $2.23 | 287,069 | 06-20-2024 |
$2.34 | $2.53 | $2.34 | $2.6 | $2.34 | 216,918 | 06-19-2024 |
$2.34 | $2.53 | $2.34 | $2.6 | $2.34 | 216,918 | 06-18-2024 |
$2.55 | $2.57 | $2.55 | $2.62 | $2.38 | 224,074 | 06-17-2024 |
$2.57 | $2.61 | $2.57 | $2.65 | $2.5 | 104,006 | 06-14-2024 |
$2.61 | $2.65 | $2.61 | $2.7067 | $2.54 | 86,161 | 06-13-2024 |
$2.65 | $2.74 | $2.65 | $2.79 | $2.63 | 91,695 | 06-12-2024 |
$2.74 | $2.66 | $2.74 | $2.74 | $2.5 | 217,366 | 06-11-2024 |
$2.68 | $2.68 | $2.68 | $2.72 | $2.56 | 149,778 | 06-10-2024 |
$2.67 | $2.71 | $2.67 | $2.72 | $2.59 | 94,324 | 06-07-2024 |
$2.71 | $2.86 | $2.71 | $2.9 | $2.62 | 320,031 | 06-06-2024 |
$2.89 | $2.79 | $2.89 | $2.94 | $2.67 | 206,746 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
ArTara Therapeutics Inc. Company Name:
TARA Stock Symbol:
NASDAQ Market:
ArTara Therapeutics Inc. Website:
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an aggregate of 118,40...
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 5t...
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...